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The LRRK2 mutation G2019S is the most common
genetic cause of Parkinson’s disease (PD). To better
understand the link between mutant LRRK2 and PD
pathology, we derived induced pluripotent stem
cells from PD patients harboring LRRK2 G2019S
and then specifically corrected the mutant LRRK2
allele. We demonstrate that gene correction re-
sulted in phenotypic rescue in differentiated
neurons and uncovered expression changes asso-
ciated with LRRK2 G2019S. We found that LRRK2
G2019S induced dysregulation of CPNE8, MAP7,
UHRF2, ANXA1, and CADPS2. Knockdown experi-
ments demonstrated that four of these genes
contribute to dopaminergic neurodegeneration.
LRRK2 G2019S induced increased extracellular-
signal-regulated kinase 1/2 (ERK) phosphorylation.
Transcriptional dysregulation of CADPS2, CPNE8,
and UHRF2 was dependent on ERK activity. We
show that multiple PD-associated phenotypes
were ameliorated by inhibition of ERK. Therefore,
our results provide mechanistic insight into the
pathogenesis induced by mutant LRRK2 and
pointers for the development of potential new ther-
apeutics.354 Cell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc.INTRODUCTIONParkinson’s disease (PD) is the second most common neurode-
generative disease worldwide and affects an estimated 1 in
1,000 people in Europe (European Brain Council, 2011).
Although most cases of PD are sporadic, about 5%–10% of
patients have familial PD (fPD) following an autosomal-recessive
or -dominant inheritance pattern (Schiesling et al., 2008). These
two inheritance forms appear to have different pathologies
(Schiesling et al., 2008). Unlike patients with autosomal-reces-
sive fPD, patients with autosomal-dominant fPD typically show
extensive formation of Lewy bodies in different parts of the brain.
Alpha-synuclein (aSYN), the protein encoded by the geneSNCA,
is the major component of Lewy bodies, indicating that aSYN
plays a central role in the pathogenesis of PD (Spillantini et al.,
1997). SNCA was the first gene identified as being mutated in
patients with fPD (Polymeropoulos et al., 1997).
In 2004, two research groups simultaneously discovered
mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene in
patients with fPD (Paisa´n-Ruı´z et al., 2004; Zimprich et al.,
2004). Like SNCA mutations, LRRK2 mutations result in auto-
somal-dominant fPD. Mutations in LRRK2 have been found in
about 2% of patients with sporadic PD (Berg et al., 2005), with
much higher prevalence rates in some populations, e.g., Ashke-
nazi Jews (Ozelius et al., 2006). Patients with PD with LRRK2
mutations most often exhibit Lewy body pathology, and experi-
ments in the mouse model have suggested a link between
LRRK2 and SNCA (Lin et al., 2009; Ross et al., 2006). G2019S
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Mechanism of Pathogenesis Induced by Mutant LRRK2is the most common mutation of LRRK2, and mutations in
LRRK2, including G2019S, have been suggested to lead to
increased expression of SNCA (Carballo-Carbajal et al., 2010;
Nguyen et al., 2011). Therefore, LRRK2 mutations are thought
to confer susceptibility to PD through SNCA (Cookson, 2010).
However, it should be noted that although most patients with
PD harboring LRRK2 mutations manifest alpha-synucleinop-
athy, patients with nigral degeneration without aSYN aggrega-
tion have been reported (Cookson et al., 2008).
Several lines of evidence suggest a role for TAU in PD
pathology. Genome-wide association studies have demon-
strated that polymorphisms at the Microtubule-associated
protein TAU (MAPT) locus, which encodes TAU, are associated
with PD. In addition, it has been shown that theMAPT haplotype
influences age at onset in LRRK2 mutation carriers (Golub
et al., 2009), and there has been at least one documented case
of a LRRK2 G2019S carrier having TAU pathology (Rajput
et al., 2006). Interestingly, it has been suggested that TAU may
colocalize with aSYN in a subset of Lewy bodies (Ishizawa
et al., 2003).
Human induced pluripotent stem cell (hiPSC) technology
offers a unique opportunity to study the mechanism of PD path-
ogenesis induced by LRRK2 G2019S, which could enable the
development of new therapies. In 2006, Shinya Yamanaka
demonstrated that expression of four genes in fibroblasts
induced the formation of pluripotent stem cells, with the same
self-renewal and differentiation potential as embryonic stem
cells (Takahashi and Yamanaka, 2006). Nguyen et al. (2011) first
demonstrated that this technology could be used to generate
iPSC lines from patients with PD harboring LRRK2 G2019S. It
was reported that differentiated midbrain dopaminergic (mDA)
neurons, which are preferentially lost in patients with PD, were
more susceptible to oxidative stress and had increased levels
of aSYN. Subsequently, Sa´nchez-Dane´s et al. (2012) showed
increased aSYN and aberrant autophagy in mDA neurons differ-
entiated from iPSC lines of PD patients with and without LRRK2
G2019S. However, PD phenotypes are affected by polymor-
phisms at multiple loci. For example, patients with LRRK2
mutations will exhibit variable phenotypes when additional poly-
morphisms are present in either SNCA or MAPT (Botta-Orfila
et al., 2012; Golub et al., 2009). As a result, it is unclear whether
these observed phenotypes in iPSC-derived neurons were
specifically due to LRRK2 G2019S. Because of the large vari-
ability in the genetic background between individuals, it is very
difficult to detect and study molecular changes resulting from
a specific allele such as LRRK2 G2019S.
Gene correction of iPSCs from patients with known genetic
mutations is a powerful tool for overcoming this limitation of
the use of iPSCs. Here, we report mechanistic insights for
mDA neurodegeneration induced by LRRK2 G2019S by using
cultures of mDA neurons differentiated from isogenic iPSC lines.
We show that targeted correction of LRRK2G2019S ameliorated
a deficit in neurite outgrowth and a defect in basal autophagy
and increased aSYN, TAU, and susceptibility to oxidative stress.
In addition, we demonstrate that targeted insertion of LRRK2
G2019S into iPSCs from a healthy donor was sufficient to reca-
pitulate the disease phenotypes. With isogenic cultures, we
were able to detect dysregulation of Copine VIII (CPNE8),
Annexin A1 (ANXA1), Microtubule-associated protein 7 (MAP7),CCalcium-dependent activator protein for secretion 2 (CADPS2),
and Ubiquitin-like with PHD and ring finger domains 2 (UHRF2),
which are involved in other neurodegenerative pathologies but
have not previously been associated with PD. Pharmacological
inhibition of LRRK2 kinase activity corrected these gene expres-
sion changes and rescued PD-associated phenotypes. Knock-
down experiments demonstrated that dysregulation of four of
these genes significantly contributed tomDA neurodegeneration
under oxidative stress. Finally, we demonstrate that LRRK2
G2019S was associated with increased activation of ERK and
that inhibition of ERK ameliorated mDA neurodegeneration, neu-
rite outgrowth, and the dysregulation of CADPS2, CPNE8, and
UHRF2. Therefore, these results reveal molecular details for
the pathogenesis of mutant LRRK2 and possible new targets
for the development of new therapeutics for patients with PD.
RESULTS
Generation and Gene Correction of iPSCs
We derived iPSCs from two patients harboring the LRRK2muta-
tion G2019S (Table S1 available online). The samples used in this
study were derived from two female patients with PD born in
1958 and 1931 (designated L1 and L2, respectively). As noniso-
genic healthy controls, we used iPSC lines derived from four
healthy women born in 1959, 1931, 1943, and 1932 (designated
C1, C2, C3, and C4, respectively) (Table S1). Dermal fibroblasts
from skin punch biopsies of patients with PD or healthy controls
were expanded and infected with retroviral expression vectors
containing the genes indicated and iPSCs were generated
(Takahashi et al., 2007). Individual clonal iPSC lines derived
from L1 and L2 were designated L1-1 and L2-1, respectively
(Table S1).
Multiple assays were used to confirm the reprogramming of
fibroblasts into all the iPSC lines used in this study. Immunostain-
ing demonstrated that the iPSC lines expressed the pluripotent
markers NANOG, OCT4, SSEA4, and TRA1-81 (Figures 1A and
S1A). Real-time quantitative PCR (qRT-PCR) analysis showed
that iPSCs expressed pluripotency markers at levels compa-
rable with human embryonic stem cells (hESCs) (Figures 1B
and S1B) and silencing of the retroviral vectors, which is a hall-
mark of bona fide iPSCs (Figure S1C; Hotta and Ellis, 2008).
Pluripotent differentiation potential of each iPSC line was tested
in vitro via embryoid body (EB)-mediated differentiation and
in vivo via teratoma formation (Figures 1C, 1D, S2A, and S2B).
Each line was verified to be euploid via microarray profiling of
single-nucleotide polymorphisms.
Genome-wide association studies have revealed that multiple
genetic variants are associated with PD (Simo´n-Sa´nchez et al.,
2009). Therefore, given the variable phenotypes associated
with specific LRRK2 mutations, it is very likely that variants in
other genetic loci modify the phenotype induced by LRRK2
G2019S. To account for this, we gene-corrected iPSC lines
from both patients to obtain three isogenic lines per patient
that differed only in this mutation. A correction vector was
inserted site specifically by cotransfecting it with zinc finger
nucleases (ZFNs) designed to introduce a double-strand break
adjacent to the G2019S mutation of the LRRK2 gene. Because
LRRK2 mutations are inherited dominantly, our patients with
PD are heterozygous for the G2019S mutation. As such, onlyell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc. 355
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Figure 1. iPSC Line Derivation and Differentiation into Functional mDA Neurons
(A) Immunostaining for the indicated markers was performed along with nuclear counterstaining by Hoechst. See also Figure S1A.
(B) qRT-PCR analysis of the indicated iPSC lines for the expression of the indicated pluripotency markers relative to HUES6 hESCs. Fibroblasts from patient 1 at
4 days after retroviral infection are also shown. See also Figures S1B and S1C. Error bars give variation from using GAPDH and BACT as housekeeping genes.
(C) Teratomas formed from subcutaneous injection of iPSCs into immunodeficient mice were isolated and stained with hematoxylin and eosin. N, neural rosettes;
E, gut-like epithelium; B, bone; M, muscle. See also Figure S2.
(D) iPSCs were differentiated in vitro via embryoid bodies and immunostained for AFP (endoderm), alpha-SMA (mesoderm), and TUBBIII (ectoderm). See also
Figure S2.
(E) Thedifferentiation protocol efficiently producesmidbrain dopaminergic neurons, shownby immunostaining for TH,MAP2, andFOXA2.See alsoFiguresS3–S5.
(F) qRT-PCR for the indicatedmarkers on the indicated days of differentiation of the iPSC line C3. Error bars show the variation of duplicate experiments. See also
Figure S3.
(G) Differentiation efficiencies for all lines, given as percentage of cells, identified by nuclei, positive for the indicated marker. n = 3–5 for each line, error bars
indicate SEM.
(H) Exemplary recording of spontaneous firing of APs in current-clamp mode. See Figure S5 for further characterization.
(I) mDA neuron cultures contain mature dopamine-producing neurons, shown by dopamine release upon stimulation of the given lines. Error bars show the
variance between two independent differentiation cultures. See also Figures S1–S5 as well as Tables S1 and S2.
All scale bars represent 100 mm.
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Mechanism of Pathogenesis Induced by Mutant LRRK2half of the targeted cell lines would be expected to target
the correct allele. We used DNA sequencing of iPSCs and
differentiated neurons to confirm correction of the G2019S
mutation (Figures S2C and S2D). As an additional experimental
control, the ZFNs were used to introduce the G2019S mutation
into one of the LRRK2 loci of the control iPSC line C4,356 Cell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc.whichwas derived from a healthy individual. Appropriate expres-
sion of the artificially mutated allele was confirmed through
quantification by pyro-sequencing with cDNA (Figure S2E).
Therefore, through both patient selection and gene targeting,
we have a complete set of iPSC lines to study the mechanisms
of PD pathogenesis induced by mutant LRRK2 (Table S1). All
Cell Stem Cell
Mechanism of Pathogenesis Induced by Mutant LRRK2gene-targeted subclones were fully characterized and con-
firmed to be euploid and pluripotent in vitro and in vivo (Figures
S1 and S2).
Gene Correction Ameliorates PD-Associated
Phenotypes in mDA Neurons
Because PD is characterized by the degeneration of mDA
neurons, we directed the differentiation of iPSCs into this
neuronal subtype. After 10 days of differentiation, we observed
efficient formation of OTX2 and FOXA2 double-positive cells,
which are markers of mDA neural progenitors (Figures S3A and
S3B). Additional developmental markers associated with the
specification of mDA neurons were detected by qRT-PCR after
13, 30, and 60 days of differentiation, including TH, FOXA2,
AADC, MSX1, LMX1A, PITX3, and NURR1 (Figures 1F, S3C,
and S3D). Immunostaining demonstrated frequent formation of
FOXA2 and TH as well as TH and LRRK2 double-positive cells
(Figures 1E and S4). The efficiency of mDA neuron formation
was approximately 20% of the total cells and 50% of all neurons
after plating them as single cells on day 30 of differentiation (Fig-
ure 1G). Cultures of differentiated mDA neurons stained posi-
tively for NURR1, which is a marker of mDA neurons, as well
as NeuN, MAP2, and SYNAPTOPHYSIN, which are markers of
mature neurons (Figures 1E, S5A, and S5B). Analysis of electro-
physiology and dopamine release upon chemical stimulation
confirmed that the differentiated neurons were functionally
mature after 30–35 days of differentiation (Figures 1H, 1I, and
S5C–S5G).
Next, we sought to determine whether the gene correction of
LRRK2 G2019S resulted in functional phenotypic correction.
Neurite shortening and sensitivity to neurotoxins are phenotypes
associated with LRRK2 G2019S (MacLeod et al., 2006; Nguyen
et al., 2011; Sa´nchez-Dane´s et al., 2012). We observed a statisti-
cally significant (p < 0.001) reduction in the velocity of
outgrowing neurites harboring LRRK2 G2019S compared to
wild-type controls (Figures 2A–2C). Targeted gene correction
of LRRK2 G2019S rescued this phenotype to a level equal to
the wild-type controls (Figures 2A and 2B). Immunostaining
showed that about 20%of outgrowing neurites were TH positive,
suggesting that this is a general neuronal phenotype and not
specific to mDA neurons (Figure 2D).
Previously, Sa´nchez-Dane´s et al. (2012), reported that LRRK2
G2019S was associated with aberrant autophagy in neurons
differentiated from iPSCs. Consistent with this report, we found
that basal autophagy was significantly reduced by about 20%
(Figures S6A and S6B) and increased numbers of autophago-
somes were observed in cultures harboring LRRK2 G2019S
(Figures S6C). Similarly, cultures of differentiated mDA neurons
were significantly more sensitive to oxidative stress when
cultured in N2 medium without the supplement B27 (Figures 3
and 4A), which contains antioxidant proteins such as Catalase
and Superoxide Dismutase (Brewer et al., 1993). Addition of
the neurotoxins rotenone or 6-hydroxydopamine (6-OHDA)
resulted in a small increase in the number of TH and cleaved
CASPASE3 double-positive cells in differentiated cultures
harboring LRRK2G2019S compared to gene-corrected isogenic
controls (Figures 3, 4A, 4B, S6D, and S6E). Immunostaining
showed that more than 80% of the cells positive for cleaved
CASPASE3 also expressed TH (Figure 4C). To further assessCthe specificity of neurodegeneration, we differentiated iPSCs
into peripheral sensory neurons (Greber et al., 2011), cultured
them under conditions of oxidative stress, and immunostained
for cleaved CASPASE3 and BRN3A, which mark apoptotic
sensory neurons. Compared to mDA neurons, fewer sensory
neurons were positive for cleaved CASPASE3, and there was
no increase associated with LRRK2G2019S (Figure S6F). These
results demonstrate that apoptosis was preferentially induced in
mDA neurons. In another experiment, we tested whether LRRK2
G2019S is sufficient to increase sensitivity of mDA neurons to
B27 withdrawal and to 6-OHDA- and rotenone-induced toxicity.
To do this, we repeated the above assays with neurons derived
from the iPSC lines C4 and C4+G2019S, in which we had in-
serted the G2019S mutation into the LRRK2 locus of an iPSC
line derived from a healthy control. The increase in cytotoxicity
was comparable in magnitude with the decrease in cytotoxicity
observed after gene correction for mutant LRRK2 iPSC lines
(Figures 3A and 4A). We conclude that mutant LRRK2 is suffi-
cient to induce increased sensitivity of human mDA neurons to
oxidative stress.
To address the question of whether the G2019S mutation
results in a gain or loss of function, we repeated the cytotoxicity
experiments in the presence of LRRK2-IN1, which is a small
molecule inhibitor of LRRK2 kinase activity. We observed
a statistically significant increase in mDA neuron survival as
measured by cleaved CASPASE3 and TH in the presence of
the inhibitor compared to controls (Figures 4D and S6G). A
similar trend was observed when cell death was quantified by
lactate dehydrogenase (LDH) release (Figures 4E and S6H).
These data suggest that LRRK2 G2019S results in a gain of
kinase function, which is consistent with previous reports
(Gloeckner et al., 2006; West et al., 2005). Therefore, multiple
phenotypic assays confirm that gene correction of LRRK2
G2019S resulted in functional phenotypic correction.
LRRK2 G2019S Causes PD-Associated Changes in TAU
and aSYN
Because multiple lines of evidence suggest a role for TAU in PD
pathogenesis, we characterized MAPT transcription and TAU
protein levels. qRT-PCR analysis on triplicate samples on day
30 of differentiation demonstrated that MAPT was significantly
downregulated by 39% in cultures of mDA neurons containing
wild-type LRRK2 compared with isogenic cultures with
G2019S LRRK2 (Figure 5A). Western blotting confirmed that
TAU protein and phospho-Thr181 TAU were significantly lower
in cultures of mDA neurons harboring gene-corrected LRRK2
compared to isogenic cultures with LRRK2 G2019S (Figures
5B, 5C, and S7A). Immunostaining confirmed that neurons ex-
pressing TH were also positive for TAU and phospho-TAU (Fig-
ure S7B). These data are consistent with previously published
data showing a link between patients with PD, MAPT, and
LRRK2. Interestingly, it has been shown that TAU enhances
aSYN aggregation and toxicity (Badiola et al., 2011). It is also
significant to note that increased levels of Thr181-phosphory-
lated TAU correlate with neurite retraction (Maldonado et al.,
2008, 2011), and, as such, could contribute to the neurite
outgrowth phenotype in LRRK2 G2019S neurons.
Because aSYN pathology is present in most patients with PD
harboring mutant LRRK2, we assessed the level of SNCAmRNAell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc. 357
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Figure 2. Gene Correction of LRRK2 G2019S Ameliorates Neurite Outgrowth Phenotype
(A) Sample pictures from a neurite outgrowth experiment for neurons differentiated from the indicated isogenic wild-type (left) and G2019S (right) LRRK2 iPSC
line. Red dots indicate the end of the neurite, which was determined every 5 min. Scale bars represent 50 mm.
(B) Individual neurite outgrowth speeds for the indicated lines measured from triplicate cultures, Error bars represent the standard error of the mean (SEM).
*p < 0.05, ***p < 0.001.
(C) When combined, the results show a significantly lower neurite outgrowth speed in neuron cultures with LRRK2 G2019S compared to wild-type. Error bars
indicate SEM.
(D) The neurite outgrowth reduction is a general neuronal phenotype, as only about 20% of the fastest outgrowing neurons are positive for TH.
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Mechanism of Pathogenesis Induced by Mutant LRRK2and aSYN protein by mDA neurons that had been differentiated
from iPSCs. qRT-PCR showed that isogenic cultures of mDA
neurons differentiated for 30 and 60 days expressed comparable
levels of SNCA (Figure 5D). Immunostaining showed that aSYN
protein in neurons differentiated for 30 days displayed a punctate
staining pattern that colocalized with SYNAPTOPHSYIN, which
is a marker of mature neurons (Figure S5B). Western blots
confirmed the presence of monomeric aSYN protein in cultures
of differentiated mDA neurons (Figure 5E). Because it has been
suggested that LRRK2 G2019S results in increased levels of
aSYN protein (Nguyen et al., 2011), we quantified the level of
aSYN normalized to GAPDH protein levels (Figure S7A). When
we initially compared all cultures of mDA neurons with either358 Cell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc.wild-type or G2019S LRRK2 without taking into account match-
ing lines from gene correction, we found no significant difference
in aSYN protein levels between groups. In contrast, when the
data was reanalyzed directly comparing the level of aSYN
present in gene-corrected cultures to the respective isogenic
cultures with LRRK2 G2019S, we found that cultures of mDA
neurons harboring gene-corrected LRRK2 contained about
30% less aSYN protein, which was statistically significant,
compared to cultures differentiated from isogenic G2019S
LRRK2 lines (Figure 5F). This is in agreement with human patho-
physiological data, which shows extensive aSYN pathology in
PD patients carrying LRRK2 G2019S (Schiesling et al., 2008).
These results are also in agreement with previously published
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Figure 3. LRRK2 G2019S Causes 6-Hydroxydopamine Sensitivity in Human mDA Neurons
(A) Relative frequency of cleaved CASPASE3 and TH double-positive cells after treating the mDA neurons differentiated from the indicated iPSC line with the
indicated concentration of 6-OHDA in N2medium (n = 2). Error bars represent the variation. Data are presented after normalization on the LRRK2WT isogenic line
that was treated with N2 medium only to correct for basal level of cell death caused by replating and N2 medium alone. For individual primary results, see
Figure S6. mDA neurons harboring LRRK2G2019S weremore susceptible to apoptosis compared to wild-type when cultured only in N2medium. Themagnitude
of the difference increased when 6-OHDA was added.
(B) All results together, after normalization by setting all mutant LRRK2 cultures to 100, show that LRRK2 G2019S causes a higher sensitivity to cytotoxic stress
when comparing mutant to their isogenic wild-type samples. Error bars show the standard deviation. ***p < 0.001 according to t test.
(C) Treatment with 10 mM6-OHDA leads to a faster increase of cell death in LRRK2 G2019S DA neurons, compared to the isogenic LRRK2WT controls. *p < 0.05,
according to the t test. Error bars indicate SEM.
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Mechanism of Pathogenesis Induced by Mutant LRRK2results (Nguyen et al., 2011; Sa´nchez-Dane´s et al., 2012).
However, we found that the difference in the level of aSYN was
not significant when comparing nonisogenic cultures because
of the high variation within the ‘‘healthy’’ neurons. This suggests
that the increase in aSYN protein levels induced by LRRK2
G2019S cannot reliably be distinguished from the variance
already present in our cultures from patients without PD.
Gene Correction Enables Identification of Novel Genes
Dysregulated by LRRK2 G2019S
To identify possible changes in gene expression caused by
LRRK2 G2019S, we compared the global gene expression
profile of cultures after 30 days of differentiation. Three indepen-
dent hiPSC lines harboring LRRK2 G2019S were differentiated
alongside their isogenic gene-corrected hiPSC lines. In addition,
two hiPSC lines derived from age- and sex-matched control
patients were differentiated. RNA was harvested and analyzed
with Illumina gene expression microarray on day 30 of differenti-
ation. The cluster dendrogram demonstrated that the gene
expression profiles of cultures differentiated from a hiPSC line
with LRRK2 G2019S was most closely related to its isogenic
gene-corrected culture in each of the three cases (Figure 6A).
In addition, we found that cultures of mDA neurons differentiated
from the healthy control hiPSC line C1-1 clustered more closelyCto cultures differentiated from hiPSC lines derived from patient 2
than to those from patient 1. This was unexpected because the
donor for hiPSC line C1-1 was age and gender matched to
patient 1. Moreover, the gene expression of cultures differenti-
ated from control line C2, which was derived from a patient
age and gender matched to patient 2, was significantly different
from all other samples. This clearly shows that derivation of
hiPSC lines from patients that are age and gender matched
does not result in closely related gene expression patterns after
differentiation even though the overall differentiation efficiencies
were comparable between all hiPSC lines. In contrast, gene
correction resulted consistently in extremely similar expression
patterns with the isogenic LRRK2G2019S hiPSC line after differ-
entiation. Given the large effect of genetic background on gene
expression, our data suggest that it is possible to detect changes
specifically associated with LRRK2 G2019S only through gene
correction.
To gain further mechanistic insight into the development of
LRRK2-related phenotypes, we sought to identify genes whose
expression levels were changed by the presence of LRRK2
G2019S. By using our previous global gene expression profiles,
we filtered for genes that were expressed at a minimum
threshold level and either up- or downregulated by at least 1.2-
fold in the same direction in all three cultures of mDA neuronsell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc. 359
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Figure 4. Gene Correction of LRRK2 G2019S Ameliorates Sensitivity of Human mDA Neurons to Rotenone
(A) Relative frequency of cleavedCASPASE3 and TH double-positive cells after treating themDAneurons of the indicated lines with the indicated concentration of
rotenone in N2medium (n = 2). Error bars represent the variation. Data are normalized to the LRRK2WT isogenic line treatedwith N2medium alone. mDA neurons
harboring LRRK2 G2019S were more susceptible to apoptosis compared to wild-type when cultured in only N2 medium. The magnitude of the difference
increased when rotenone was added.
(B) LRRK2 G2019S causes a higher sensitivity to cytotoxic stress when compared with the wild-type isogenic line caused by rotenone. Error bars show the
standard deviation. These are combined data for isogenic lines L1-1, L1-2, L2-2, L2-3, and C4 at all concentrations used.
(C) Cleaved CASPASE3 was preferentially in cells expressing TH after treatment with the indicated conditions. Error bars indicate variation.
(D and E) 1.5 mM LRRK2-IN1, which inhibits LRRK2 kinase activity, rescued mDA neurons from apoptosis. Cultures were differentiated in triplicate from L1-1Mut
and C4+G2019S, stressed with 50 nM rotenone, and immunostaining for cleaved CASPASE3 and TH double-positive cells (D) and LDH release (E) compared to
DMSO-treated controls. Error bars indicate SEM.
**p < 0.01 and ***p < 0.001 according to t test. See also Figure S6.
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Mechanism of Pathogenesis Induced by Mutant LRRK2differentiated for 30 days from hiPSCs containing LRRK2
G2019S compared to gene-corrected LRRK2. Subsequently,
we differentiated these and additional hiPSC lines in indepen-360 Cell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc.dent triplicate cultures for 30 days followed by qRT-PCR valida-
tion. Six genes could be corroborated by further samples
by qRT-PCR as significantly and consistently dysregulated
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Figure 5. LRRK2 G2019S Mutation Leads to Increased Expression of MAPT mRNA and TAU Protein as well as Increased aSYN Protein
(A) MAPT mRNA levels are significantly decreased when comparing triplicate cultures differentiated from LRRK2 wild-type to isogenic mutant lines. n = 6 lines
wild-type, n = 5 mutant, including C4 and C4+G2019S.
(B) Representative western blot results for the given mDA neuron cultures. Independent replicate experiments are shown for lines L2-3Mut and L2-3GC.
(C) Reduced TAU and phospho-TAU (Thr181) protein is found in cultures differentiated from LRRK2 wild-type compared to isogenic mutant lines. This is an
average of individual results shown in Figure S7.
(D) No change in expression is detected by qRT-PCR analysis of SNCA expression in mDA neuron cultures differentiated in independent replicate cultures
comparing all targeted lines to their isogenic mutant line. n = 3–5 for each line at day 30, n = 2–3 for each line at day 60 of differentiation.
(E) Representative western blot results for the given mDA neuron cultures for aSYN protein showing lower levels in wild-type compared to isogenic mutant
samples. aSYN protein levels were normalized using GAPDH as a housekeeping gene.
(F) Average aSYN protein abundance showing a significant decrease in gene-corrected lines compared to their mutant isogenic lines. n = 9, individual results are
shown in Figure S7.
Error bars indicate SEM in all panels. *p < 0.05, **p < 0.01, ***p < 0.001 according to t test.
Cell Stem Cell
Mechanism of Pathogenesis Induced by Mutant LRRK2by LRRK2G2019S in cultures of mDA neurons. The first four that
we identified were CPNE8, ANXA1,MAP7, and CADPS2, which
were downregulated by about 38%, 40%, 30%, and 29%,
respectively, in cultures of mDA neurons harboring gene-cor-
rected LRRK2 compared to isogenic cultures with the G2019S
mutation (Figure 6B). In addition, we identified UHRF2 as signif-
icantly upregulated by 16% in cultures of mDA neurons
harboring gene-corrected LRRK2 compared with the isogenic
cultures with the G2019S mutation (Figure 6B). To confirm the
effect of LRRK2 G2019S on the expression of these genes, we
repeated the experiment with cultures differentiated from the
hiPSC line C4, which was derived from a healthy control patient,
and from the hiPSC line C4-G2019S, in which the mutation
G2019S had been specifically introduced into one endogenous
LRRK2 allele. The results were consistent with the gene-cor-
rected cultures (Figure 6C). Western blotting demonstrated
that protein levels of CPNE8, CADPS2, ANXA1, and MAP7
were significantly altered in cultures with mutant LRRK2
compared with isogenic controls (Figures 6D and 6E). UHRF2
was lower in LRRK2 G2019S samples compared with isogenic
controls with a p value of 0.0533 (Figures 6D and 6E). Inhibition
of LRRK2 kinase activity with LRRK2-IN1 rescued the dysregu-
lation of these genes (Figure S6I). Therefore, isogenic culturesCenabled the detection of multiple genes that were specifically
dysregulated by LRRK2 G2019S.
Knockdown experiments were used to assess the contri-
butions of CPNE8, ANXA1, MAP7, CADPS2, and UHRF2 to
mDA neurodegeneration under oxidative stress. Cultures of
mDA neurons differentiated from iPSC line L1-1Mut were treated
with Accell siRNASMARTpool targeting one of the identified dys-
regulated genes. qRT-PCR demonstrated that the target gene
expression was decreased by 50%–80% (Figure 6F). After expo-
sure to oxidative stress via B27 withdrawal alone or in combina-
tion with 50 nM rotenone, neurodegeneration was assessed by
LDH release and double-immunostaining for cleavedCASPASE3
and TH. We found that knockdown of CPNE8, CADPS2, and
MAP7 resulted in a statistically significant decrease in the
number of cleaved CASPASE3 and TH double-positive neurons
(Figures 6G and 6H). In contrast, we found that knockdown of
UHRF2 resulted in small, but significant, increase in the number
of cleaved CASPASE3 and TH double-positive neurons (Figures
6G and 6H). No significant change was observed with the knock-
down of ANXA1 (Figures 6G and 6H). Knockdown of CPNE8,
CADPS2, and MAP7 was also protective when we used LDH
release as a measure of cytotoxicity (Figures S6J and S6K).
These results demonstrate that the upregulation of CPNE8,ell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc. 361
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Figure 6. Identification and Validation of Novel Genes Contributing to PD-Associated Phenotypes Induced by LRRK2 G2019S
(A) Cluster analysis of the whole-genome expression profile after 30 days differentiation of the indicated cell lines. Only isogenic iPSC lines give extremely
comparable differentiation outcome. Interestingly, C1 clusters closer to L2 and C2 closer to L1, which is opposite to their matches based upon age and gender.
(B) Candidate genes dysregulated by LRRK2G2019S from themicroarray data were validated by qRT-PCR onmDA neuronal cultures differentiated for 30 days in
triplicates from isogenic hiPSC lines L1-1Mut with L1-1GC1 and L1-1GC2, L1-2Mut and L1-2GC, L2-2Mut and L2-2GC, L2-3Mut and L2-3GC.
(C) hiPSC line C4 and the isogenic line C4+G2019S were differentiated and analyzed by qRT-PCR for the candidate genes. Error bars represent SEM.
(legend continued on next page)
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Figure 7. LRRK2 G2019S Causes Increased ERK Phosphorylation that Is Responsible for Some of the Observed Phenotypes
(A)Western blot for phosphorylatedERK1/2 (pERK) and ERK1/2 (ERK) on neurons differentiated for 30 days and cultured under the indicated conditions for 2 days.
(B) Representative western blot images of pERK and ERK of mDA neuronal cultured differentiated in duplicate for 30 days from the indicated lines.
(C) Quantification of the data from (B) showing significantly increased pERK in cultures harboring LRRK2 G2019S compared to isogenic controls.
(D) Representative western blot for the indicated marker for differentiated cultures from the indicated lines treated for 6 days with 1.5 mM LRRK2-IN1 alongside
the DMSO-treated control.
(E) Quantification of the effect of LRRK2-IN1 on pERK with lines L1-1Mut, L2-2Mut, L2-3Mut, and C4+G2019S in duplicates of treatment, alongside their DMSO-
treated controls for 6 days.
(F and G) mDA cultures of the line L1-1Mut at day 30 of differentiation were treated for 2 days with PD0325901 (ERK-IN), an ERK phosphorylation-inhibitor, at the
given concentrations, which reduced cytotoxicity from stress with 50 nM rotenone as measured by LDH release (F) and cleaved CASPASE3 and TH double-
positive cells (G) compared to DMSO-treated controls.
(H) Neurite outgrowth assay on neurons differentiated for 30 days and treated with the indicated compounds compared to DMSO-treated controls.
(I) qRT-PCR for the indicated genes on neurons differentiated for 30 days and treated with ERK-IN relative to DMSO-treated controls.
*p < 0.05, **p < 0.01, ***p < 0.001 according to t test. Error bars represent SEM in all panels.
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Mechanism of Pathogenesis Induced by Mutant LRRK2CADPS2, andMAP7 by LRRK2 G2019S contributes to the mDA
neurodegenerative phenotype observed. The small, but signifi-
cant, increase in mDA degeneration resulting from UHRF2
knockdown is consistent with the small decrease in UHRF2
expression observed in cultures with LRRK2 G2019S. Western
blotting after knockdown of MAP7 reduced aSYN by about
50% in cultures differentiated from iPSCs harboring LRRK2
G2019S (Figures S7C and S7D). Knockdown of CADP2 and
CPNE8 had mildly reduced aSYN, but knockdown of UHRF2
and ANXA1 had no effect (Figures S7C and S7D).
Higher Sensitivity of LRRK2 G2019S Neurons to
Oxidative Stress Involves the Activation of ERK
Previously, it was shown that LRRK2 G2019S causes abnor-
malities in basal autophagy in fibroblasts through activation of(D) Representative western blot pictures for the newly identified genes from the
indicated isogenic lines. TBP and a-TUBULIN (TUB) were used as loading contro
(E) Densitometric quantification of the western blots from (D). For ANXA1 and
additionally used. Error bars indicate SEM.
(F) Knockdown efficiency was determined by qRT-PCR for the indicated genes
30 days from the line L1-1Mut. Error bars show the variance from two parallel cu
(G and H) Knockdown of CADPS2, CPNE8, MAP7, and UHRF2 but not ANXA1 h
medium alone (G) or N2 supplemented with 50 nM rotenone (H), as measured by
represent SEM.
*p < 0.05 and **p < 0.01 according to t test.
CERK1/2 (ERK) (Bravo-San Pedro et al., 2013). In addition, neu-
rite shortening by LRRK2 G2019S has been linked to ERK
signaling (Plowey et al., 2008). For these reasons, we per-
formed western blotting to quantify the level of phosphorylated
ERK1/2 (pERK), which is the active form of ERK. Cultures of
mDA neurons had increased pERK levels after B27 withdrawal
compared to controls, and addition of rotenone further
increased levels of pERK (Figure 7A). Untreated mDA cultures
harboring wild-type LRRK2 had 50% less pERK compared to
isogenic cultures with LRRK2 G2019S (Figures 7B and 7C).
When cultures of mDA neurons were treated with LRRK2-IN1,
pERK levels were significantly decreased by more than 40%
(Figures 7D and 7E). Treatment with PD0325901 (hereafter
ERK-IN), an inhibitor of ERK phosphorylation, rescued cultures
of mDA neurons from degeneration and reduced overallindicated lines taken at day 30 of duplicate differentiation cultures from the
ls.
CADPS2, duplicate cultures differentiated from L2-2Mut and L2-3Mut were
normalized to nontargeting controls in mDA neuron cultures differentiated for
ltures.
ad a significant effect on the sensitivity of mDA neurons when treated with N2
the amount of cleaved CASPASE3 and TH double-positive neurons. Error bars
ell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc. 363
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Mechanism of Pathogenesis Induced by Mutant LRRK2cytotoxicity when treated with oxidative stress (Figures 7F
and 7G). Finally, ERK-IN and LRRK2-IN1 increased neurite
outgrowth of differentiated neurons compared to DMSO-
treated controls (Figure 7H). Therefore, LRRK2 G21019S leads
to activation of ERK, which contributes to the mDA neurode-
generative phenotype observed in vitro.
We next tested whether activation of ERK contributed to the
dysregulation of our newly identified genes. To do this, qRT-
PCR was performed on cultures of mDA neurons treated with
ERK-IN for 4 days. We observed that expression of CADPS2,
CPNE8, and UHRF2 was significantly altered by ERK inhibition
in the opposite direction compared to that induced by LRRK2
G2019S (Figure 7I). Taken together, these results suggest that
CADPS2, CPNE8, and UHRF2 expression is dysregulated by
LRRK2 G2019S through aberrant ERK activation. However,
the results for ANXA1 and MAP7 suggest that LRRK2 G2019S
might also contribute to PD phenotypes through additional
mechanisms.
DISCUSSION
Reprogramming is a breakthrough technology that enables the
generation of patient-specific stem cells. By using patients
with PD-causing mutations, such as LRRK2 G2019S, it is
possible to derive iPSCs that recapitulate aspects of PD
pathology (Nguyen et al., 2011; Sa´nchez-Dane´s et al., 2012).
However, because of variance in genetic backgrounds, which
is likely to arise from polymorphisms in other genes, each indi-
vidual might behave differently with respect to a given mutation.
Recently, Liu et al. (2012) reported the derivation of iPSCs from
PD patients harboring LRRK2 G2019S as well as isogenic
gene-corrected controls. The authors demonstrated phenotypic
changes in the nuclear envelope. Although interesting, these
changes lack a clear causal link to PD pathogenesis. In addition,
the authors studied primitive neural stem cells, which are most
closely related to cells present in early post-implantation-stage
embryos that are not present in fetuses, neonates, or adults
(Hitoshi et al., 2004; Liu et al., 2012). Therefore, there is still sig-
nificant potential for gene-corrected iPSCs to elucidate the
molecular mechanisms underlying PD pathogenesis in mDA
neurons.
Here, we have demonstrated that neurons differentiated from
iPSCs derived from patients with PD harboring LRRK2 G2019S
exhibit multiple phenotypes including reduced neurite outgrowth
and increased sensitivity to stress. By using gene-corrected
isogenic cultures and the introduction of the mutation into
a control iPSC line, we show that these phenotypes were specif-
ically associated with LRRK2 G2019S. Because an inhibitor of
LRRK2 kinase activity ameliorated these phenotypes, the
G2019S mutation probably results in increased kinase activity,
which is consistent with previous reports (Gloeckner et al.,
2006; West et al., 2005).
Gene correction enabled the discovery of genes that con-
tribute to PD-associated phenotypes in cultured mDA neurons
induced by LRRK2 G2019S. Expression profiling of multiple
pairs of isogenic cultures resulted in the identification of a handful
of genes that were consistently dysregulated by LRRK2G2019S
including CPNE8, CADPS2, MAP7, and UHRF2. Western blot-
ting confirmed differences in the level of protein, and siRNA364 Cell Stem Cell 12, 354–367, March 7, 2013 ª2013 Elsevier Inc.experiments demonstrated that this dysregulation contributed
to mDA degeneration.
Interestingly, these genes have previously been implicated in
neurodegenerative phenotypes in multiple ways. Polymor-
phisms in CPNE8 have been shown to affect the incubation
time of prion disease in mice (Lloyd et al., 2010). Interestingly,
PD has been proposed to be a prion-like disease involving
aSYN (Polymenidou and Cleveland, 2012). We could confirm
previous reports of increased levels of aSYN with mutant
LRRK2 (Nguyen et al., 2011; Sa´nchez-Dane´s et al., 2012). It is
possible that the reported defects in autophagy induced by
LRRK2 G2019S contribute to the increased level of aSYN
protein because there is no detectable increase in SNCA
transcription.
UHRF2 is an E3 ubiquitin ligase with the same catalytic activity
as PARKIN. Because loss-of-function mutations in PARKIN
cause PD, the downregulation of UHRF2 in cultures of mDA
neurons containing the PD-associated mutation LRRK2
G2019S is significant. In addition, UHRF2 has previously been
shown to enhance clearance of polyglutamine aggregates,
which cause neurodegeneration in several diseases (Iwata
et al., 2009). It is tempting to speculate that UHRF2 could play
a similar role for aSYN. Consequently, the increased levels of
CPNE8 and aSYN and decreased levels of UHRF2 proteins
suggest that LRRK2 G2019S could act on multiple mechanisms
to increase the initiation of synucleinopathy.
CADPS2 dysregulation also has potentially significant implica-
tions for mDA neurodegeneration. The protein CADPS2 has
been demonstrated to regulate the neurotransmission of mono-
amines, of which dopamine is an example (Brunk et al., 2009).
This is of interest because transgenic mice overexpressing
LRRK2 variants show dysregulation of dopamine release (Li
et al., 2010). Dopamine is thought to increase oxidative stress
in mDA neurons through the formation of reactive metabolites
(Napolitano et al., 2011). Consequently, dysregulation of
CADPS2 by LRRK2 G2019S could result in aberrant formation
of toxic metabolites. Consistent with this idea, increased oxida-
tive stress, for example by administration of rotenone, is known
to induce PD-like pathogenesis and induced mDA-specific neu-
rodegeneration in vitro in our differentiated hiPSC cultures (Inden
et al., 2011).
Because LRRK2 is not a transcription factor, additional
proteins probably mediate the transcriptional dysregulation we
observed. We have shown that LRRK2 G2019S resulted in
increased phosphorylation of ERK in cultures of human mDA
neurons. Inhibition of ERK activity rescued mDA neurons in our
system, which suggests that ERK activity is crucial for the path-
ogenesis of mutant LRRK2. Two previously published reports
could account for the link of LRRK2 with ERK. First, Ste20 family
kinases, which are upstream of ERK and are induced by stress,
are phosphorylated by LRRK2 protein (Zach et al., 2010).
Second, it has been shown that Endophilin A1 is directly phos-
phorylated by LRRK2 (Matta et al., 2012). Consistent with this
finding, knockdown of Endophilin A1 resulted in decreased
ERK activation by BDNF (Fu et al., 2011). It is also significant
to note that the autophagy defect caused by LRRK2 has also
been linked to ERK activity (Bravo-San Pedro et al., 2013). Taken
together, our results suggest possible targets for the develop-
ment of new therapeutics for patients with PD.
Cell Stem Cell
Mechanism of Pathogenesis Induced by Mutant LRRK2EXPERIMENTAL PROCEDURES
Generation of Induced Pluripotent Stem Cells
Informed consent was obtained from all patients involved in our study prior to
cell donation. The Ethics Committee of the Medical Faculty and the University
Hospital Tu¨bingen previously approved this consent form. Dermal fibroblasts,
obtained from skin biopsies of patients with PD and healthy controls, were
cultured. Reprogramming was adapted from Takahashi et al. (2007). Human
iPSCs were cultured on mitomycin C (Tocris)-inactivated MEFs. Gene correc-
tion was performed by nucleofection of ZFN constructs targeting LRRK2
(Sigma). 50 mg/ml G418 (PAA) 2 mM ganciclovir (Sigma)-resistant colonies
were picked and clonally expanded on MEFs.
iPSC Differentiation into mDA Neurons
mDA neurons were generated via adapted protocol (Chambers et al., 2009;
Nguyen et al., 2011). Confluent iPSCs were cultured with 1 mM dorsomorphin
(Tocris), 10 mM SB431542, and 0.5 mM purmorphamine (PMA, Alexis).
mDA patterning was performed with N2 medium supplemented with 0.5 mM
PMA, 100 ng/ml human FGF8, 20 ng/ml human BDNF (both Peprotech), and
200 mM ascorbic acid (AA, Sigma). Maturation was induced by culturing
with BDNF, AA, GDNF, TGF-b, and dbcAMP. mDA neuron differentiation
cultures were replated as single cells on about day 30 on Matrigel-coated
48-well plates.
Protein Analysis
Cell pellets of differentiated neurons were extracted with RIPA-Buffer contain-
ing protease inhibitors (Mini complete, Roche) on ice. Supernatant were mixed
with 63 Laemmli buffer. 15 mg of the protein lysate were loaded on a 4%–12%
gel (NuPAGE, Invitrogen) after incubation at 95C for 5 min and then blotted on
a PVDF membrane. The membrane was blocked and incubated with the indi-
cated primary antibodies (listed in Supplemental Information). After 33
washing, the blot was incubated with HRP coupled secondary antibody. The
membrane was washed and then developed with chemiluminescent HRP
substrate solution (Millipore, GE). Protein bands were standardized on
GAPDH, TBP, b-actin, or a-TUBULIN.
Quantification of the Cytotoxicity of 6-OHDA and Rotenone
mDA neuron differentiation cultures on days 27–35 were disaggregated and
plated as single cells. 2 days later, cultures were fed with N2 medium without
supplements for 6 hr. This medium was replaced with warm N2 medium
supplemented with 10 mM 6-OHDA, 2 mM 6-OHDA, 50 nM rotenone, or
100 nM rotenone and incubated for 48 hr. Afterwards, the cell cultures were
fixed and stained.
Quantitative RT-PCR
Total RNA was isolated from cell culture samples with RNeasy columns
(QIAGEN) including on-column DNA digestion. cDNA was prepared with
oligo-dT16 primers (Metabion) and M-MLV reverse transcriptase (USB).
Cycling was carried out on an ABI 7300 Real-Time PCR system. Relative
expression levels were calculated via the 22D method, based on biological
reference samples and housekeeping genes for normalization. Primer
sequences are listed in Table S2.
Whole-Genome Expression Analysis
DNA-free total RNA samples (500 ng) to be hybridized on Illumina human-12
V3 expression BeadChips were processed with a linear amplification kit
(Ambion) generating biotin-labeled cRNA (IVT duration: 14 hr). Raw data
were background subtracted and normalized via the ‘‘cubic spline’’ algorithm.
Data analysis was done with MS Excel and R (Bioconductor, pvclust).
Gene Knockdown
Self-transfecting Accell siRNA (nontargeting green fluorescent control,
ANXA1, CADPS2, CPNE8, MAP7, UHRF2; Thermo) SMARTPool are
mixtures of four siRNAs targeting a single gene. siRNA was diluted in matu-
ration medium and added to the cells twice every other day (for RNA extrac-
tion). For the cytotoxicity experiments, siRNA was added starting 2 days
before reseeding, during reseeding, and 2 days later during the stressing
procedure.CInhibitor Treatment
For RNA and protein sample isolation, mDA neuron cultures were treated with
maturation medium supplemented with 1.5 mM LRRK2-IN1 for 6 days and
0.5 mM PD0325901 (both Merck) for 2–4 days and compared to DMSO alone.
Medium was changed every other day. For determining neural survival,
cultures were treated starting 2 days before reseeding.ACCESSION NUMBERS
The data have been deposited in GEO at NCBI under the accession number
GSE43364.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.01.008.
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